Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613666 | 0.90 | P2RX7 (0.42) | GRM2PARP1P2RX7 | |
| SCHEMBL13613660 | 0.88 | PARP1 (0.48) | KMT2AMEN1PARP1ALDH1A1 | |
| SCHEMBL2022902 | 0.87 | KMT2A (0.39) | KMT2AMEN1PARP1P2RX7ALDH1A1 | |
| SCHEMBL13613675 | 0.86 | CHRM5 (0.42) | GRM2P2RX7 | |
| SCHEMBL2023664 | 0.86 | KMT2A (0.38) | KMT2AMEN1GRM2PARP1ALDH1A1 | |
| SCHEMBL13613663 | 0.86 | GRM2 (0.56) | GRM2ALDH1A1 | |
| SCHEMBL13613672 | 0.85 | FNTA (0.42) | GRM2ALDH1A1 | |
| SCHEMBL8271878 | 0.84 | KMT2A (0.41) | KMT2AMEN1GRM2PARP1ALDH1A1 | |
| SCHEMBL2022812 | 0.84 | KMT2A (0.41) | KMT2AMEN1GRM2PARP1ALDH1A1 | |
| SCHEMBL1002963 | 0.84 | HTR2A (0.38) | KMT2AMEN1GRM2PARP1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | KMT2A 3975/4885MEN1 2588/4885GRM2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.